There have been some changes [1] in recent years attempting to address this. Since 2007, all drug, biologic, and device trials in the US must be registered with ClinicalTrials.gov after phase 1 (which, at least in principle, addresses safety only - not efficacy), and "results" must be reported. There could certainly be some loopholes or limitations on the data release that I am unaware of.
However, it is true that most of the controversial, blockbuster drugs that are discussed in the original article were approved long before these requirements came into effect.